Added 24 days ago Drug news
BioCryst Pharmaceuticals, Inc. announced that the randomized (n=121), double-blind, placebo-controlled, Phase III APeX-2 trial of once-daily, oral BCX 7353 for...
Added 2 months ago Drug news
ADMA Biologics, Inc. announces that the FDA has approved Asceniv Immune Globulin Intravenous, Human – slra 10% Liquid, formerly referred...
Added 5 months ago Drug news
Complete Response Letter from FDA for Bivigam relating to the drug substance PAS submission.- ADMA Biologics
ADMA Biologics, Inc. announced that the FDA has issued a Complete Response Letter for the drug substance Prior Approval Supplement...
An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.
EADV Congress 2018: Bringing you the latest news and insights from 27th EADV Congress, 12-16 September 2018 Paris, France.
Experts discuss the use of non-vitamin K oral anticoagulants in the treatment and prevention of stroke, deep vein thrombosis and pulmonary embolism in atrial fibrillation patients.
See information on best practice in solid organ transplantation, and expert discussions on related hot topics.
The Atopic Dermatitis Knowledge Centre is an educational resource, intended for healthcare professionals, that provides credible medical information on the epidemiology, pathophysiology and burden of atopic dermatitis, as well as diagnostic techniques, treatment regimens and guideline recommendations.
ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients
This part of the European Fungal Infection Study Group (EFISG) of the European Society of Clinical Microbiology and Infectious Diseases...
Added 6 years ago
Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies.
In patients with primary antibody deficiencies, subcutaneous administration of IgG (SCIG) replacement is effective, safe, well-tolerated, and can be self-administered at home. A new SCIG replacement at 20% concentration (Hizentra®)...
Added 1 year ago
Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection.
Rituximab, a monoclonal antibody that targets CD20 on B cells, is now central to the treatment of a variety of malignant and autoimmune disorders.
Added 2 years ago
Human immunoglobulin 10 % with recombinant human hyaluronidase: replacement therapy in patients with primary immunodeficiency disorders
Human immunoglobulin is an established replacement therapy for patients with primary immunodeficiency disorders (PIDs). Recombinant human hyaluronidase (rHuPH20) is a...
Added 4 years ago
Lauren McCracken works for our sister agency Digital Medical Communications (DMC Ltd) as an Associate Medical Writer. Lauren is very passionate about healthcare and how technology can improve treatments, and has written a blog series 'Transforming lives through technology'... Read more
When should AIT be used to treat your patients with allergies? Is it right for every allergy? And do we really know the long-term effects of this treatment? This blog highlights some of the talking points surrounding AIT discussed at this year’s EAACI Congress.